Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review
Adjuvant endocrine therapy (AET) significantly reduces recurrence and mortality in women with breast cancer (BrCa). Despite the efficacy of AET in improving BrCa outcomes, up to 50% of women do not adhere to prescribed AET regimens. While numerous demographic and clinical predictors influence adherence and persistence, few studies have identified the patient-reported factors that influence AET adherence and persistence.
The aim was to examine the patient-reported personal, social, and structural factors influencing BrCa survivors’ adherence and persistence with AET.
An integrative review was undertaken wherein PubMed, Medline, CINAHL, Embase, and PsycINFO databases were searched using keyword descriptors and database subject headings. Inclusion criteria included quantitative or qualitative peer-reviewed studies written in English that assessed AET adherence and/or persistence through objective measurement or self-report and included patient-reported factors found to influence adherence and/or persistence. The data extracted from eligible studies were entered into a matrix, and systematically compared and iteratively analyzed using relational autonomy as an organizing theoretical framework.
A total of 43 manuscripts (9 qualitative and 34 quantitative) were reviewed. Several personal, social, and structural factors were identified that influenced AET adherence and persistence, including side effects, necessity beliefs, self-efficacy, the patient–healthcare provider relationship, social support, and continuity of follow-up care.
An increasing number of studies have focused on identifying the patient-reported factors that influence AET adherence and persistence. This review highlights important personal, social, and structural factors that act as facilitators and barriers in adhering to and persisting with long-term AET. Acknowledging and addressing these factors is key to providing women with the care needed to improve suboptimal adherence and persistence.
KeywordsBreast cancer Adjuvant endocrine therapy Medication adherence Medication persistence Integrative review Cancer survivorship Patient-reported outcomes
Adjuvant endocrine therapy
Quality of life
LKL was supported by a University of British Columbia Four-Year Fellowship and a CIHR Psychosocial Oncology Research Training (PORT) Fellowship.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.International Agency for Research on Cancer (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- 2.Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792. https://doi.org/10.1097/01.ogx.0000201966.23445.91 CrossRefPubMedGoogle Scholar
- 3.Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796. https://doi.org/10.1200/JCO.2009.26.3756 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. https://doi.org/10.1200/JCO.2013.54.2258 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816. https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.van Herk-Sukel MPP, van de Poll-Franse LV, Voogd AC et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122:843–851. https://doi.org/10.1007/s10549-009-0724-3 CrossRefPubMedGoogle Scholar
- 17.Cahir C, Guinan E, Dombrowski SU et al (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: a systematic review and meta-analysis. Patient Educ Couns 98:1524–1539. https://doi.org/10.1016/j.pec.2015.05.013 CrossRefGoogle Scholar
- 19.World Health Organization (2003) Adherence to long-term therapies: evidence for action. WHO, GenevaGoogle Scholar
- 20.U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79. https://doi.org/10.1186/1477-7525-4-79 CrossRefGoogle Scholar
- 25.Sherwin S (1998) A relational approach to autonomy in health care. In: Sherwin S (ed) Politics of women’s health. Exploring agency and autonomy. Temple University Press, Philadelphia, pp 19–47Google Scholar
- 49.Hadji P, Jackisch C, Bolten W et al (2014) COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol 25:372–377. https://doi.org/10.1093/annonc/mdt513 CrossRefPubMedGoogle Scholar
- 52.Hershman DL, Kushi LH, Hillyer GC et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157:133–143. https://doi.org/10.1007/s10549-016-3788-x CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Huiart L, Bouhnik A-DD, Rey D et al (2013) Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS ONE 8:e81677. https://doi.org/10.1371/journal.pone.0081677 CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Wells KJ, Pan TM, Vázquez-Otero C et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130. https://doi.org/10.1007/s00520-016-3229-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28:634–640. https://doi.org/10.1200/JCO.2009.23.5150 CrossRefPubMedGoogle Scholar
- 71.Hadji P, Blettner M, Harbeck N et al (2013) The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mds653 Google Scholar
- 72.Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 23:393–399. https://doi.org/10.1016/j.breast.2014.02.009 CrossRefPubMedGoogle Scholar
- 74.Kirchner TR, Shiffman S (2013) Ecological momentary assessment. In: Wiley-Blackwell handbook of addiction psychopharmacology. 10.1002/9781118384404.ch20